• If you are wondering whether Medtronic stock offers reasonable value or if the recent price levels are stretching it, the current setup gives you a lot to weigh up.
• The shares recently closed at US$81.32, with the price down 0.8% over the last week, up 6.8% over the last month, modestly up 0.8% over three years and down 15.3% year to date and 25.2% over five years, which hints that the market has been reassessing both its potential and its risks.
• These mixed returns sit against a backdrop of ongoing interest in large healthcare equipment companies like Medtronic, as investors weigh their role in portfolios that seek stability alongside exposure to medical technology. Recent coverage has focused on how the stock fits into defensive healthcare allocations and how its profile compares with other established medical equipment peers.
• On Simply Wall St's 6 point valuation framework, Medtronic scores 5 out of 6, which sets up a closer look at how different valuation approaches assess the stock today and points to an even more useful way to think about valuation that will be discussed at the end of this article.

Approach 1: Medtronic Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what Medtronic stock might be worth by projecting its future cash flows and discounting them back to today in dollar terms. The idea is simple: you are asking what those future dollars are worth right now.

For Medtronic, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month Free Cash Flow is about $5.43b. Analysts provide explicit Free Cash Flow estimates for the next few years, and Simply Wall St then extends those out to a 10 year view, with projected Free Cash Flow of about $7.20b in 2035 based on a mix of analyst inputs and extrapolated figures.

Pulling those cash flows back to today gives an estimated intrinsic value of US$83.78 per share. Against the recent share price of US$81.32, the model suggests Medtronic is about 2.9% undervalued, which sits within a fairly tight band around the current market price.

Result: ABOUT RIGHT

Medtronic is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Approach 2: Medtronic Price vs Earnings

For a profitable company like Medtronic, the P/E ratio is a useful yardstick because it links what you pay for the stock to the earnings the business is generating today. Investors usually accept a higher P/E if they expect stronger earnings growth or see the stock as relatively lower risk, and look for a lower P/E when growth expectations are modest or risks are higher.

Medtronic currently trades on a P/E of about 21.7x. That sits below the Medical Equipment industry average P/E of about 24.9x and further below the peer group average of roughly 32.5x, so the stock is priced at a discount to these broad benchmarks. Simply Wall St’s Fair Ratio for Medtronic is 26.6x. This Fair Ratio is a proprietary view of what a reasonable P/E might be, based on factors such as earnings growth characteristics, industry, profit margins, market value and company specific risks.

Compared with simple peer or industry comparisons, the Fair Ratio can provide a more tailored reference point because it adjusts for Medtronic’s own profile rather than assuming all Medical Equipment stocks deserve similar multiples. With the current P/E of 21.7x below the Fair Ratio of 26.6x, the stock screens as undervalued on this measure.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Medtronic Narrative

Earlier it was mentioned that there is an even better way to understand Medtronic stock valuation. Narratives are introduced here as simple stories that connect your view of the company to a set of financial forecasts and a Fair Value estimate that you can compare with the current price on Simply Wall St’s Community page.

Each Narrative lets you spell out how you think Medtronic’s revenue, earnings and margins might evolve, links those assumptions to a Fair Value, and then shows whether that Fair Value sits above or below today’s price to help you consider whether the stock looks closer to a buy, a hold, or a potential sell based on your own framework.

These Narratives stay current because they are refreshed when new information such as earnings releases or news is added. Your Medtronic view is therefore not fixed in time but adjusts as the story and the numbers change.

For example, one Medtronic Narrative on Simply Wall St anchors to a lower Fair Value of US$78.00, with assumptions such as 2.0% annual revenue growth, profit margins near 16.0% and a future P/E of about 21.0x. Another uses a higher Fair Value of US$105.76, built on 4.6% revenue growth, margins near 15.8% and a future P/E around 27.4x. This shows how different perspectives on the same company can reasonably lead to very different conclusions.

For Medtronic, we will make it straightforward for you with previews of two leading Medtronic Narratives:

Start by asking which of these summaries feels closer to how you see Medtronic stock today. Then use that as the base case to test your own assumptions on revenue, margins and valuation.

Fair Value: US$105.76

Gap to this Fair Value vs the recent price of US$81.32: about 23.1% below that Fair Value level

Revenue growth assumption: 4.6% a year

• Analysts in this camp see Medtronic’s chronic disease exposure, digital health, robotics and AI enabled devices, and broader product portfolio as support for mid single digit revenue growth and higher earnings over time.
• They factor in margin improvement from restructuring, the Diabetes separation and a tilt toward higher margin product areas, with profit margins modeled to rise from 13.0% to 15.8% by around 2029.
• This view assumes the stock trades on a future P/E of 27.4x those earnings and arrives at a Fair Value of US$105.76 that sits above the recent share price.

Fair Value: US$78.00

Gap to this Fair Value vs the recent price of US$81.32: about 4.3% above that Fair Value level

Revenue growth assumption: 2.0% a year

• The more cautious view still acknowledges growth areas like electrophysiology, hypertension devices, robotics and neuroscience, but assumes they translate into only low single digit revenue growth across the group.
• It builds in margin improvement from 13.2% to 16.0% by 2029 yet pairs that with a lower future P/E of 21.0x, reflecting concerns that Medtronic may warrant a discount to the wider US Medical Equipment sector.
• On these assumptions, the Fair Value of US$78.00 comes out slightly below the recent share price, which leaves less room if execution or growth fall short of expectations.

If neither preview quite fits your view of Medtronic, you can adjust the revenue growth, margin and P/E inputs to create a version that matches your own expectations, then track how the stock price moves against that Fair Value over time.

Do you think there's more to the story for Medtronic? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.